StockData
NXLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

Nexalin Technology, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.36+0.01 (+0.43%)

Close on Oct 19, 2026

Market cap
$49.90M
P/E (TTM)
–
Dividend yield
–

Nexalin Technology, Inc. revenue by segment

By business segment

By product or service

RevenueQ2 26Q1 26Q2 25Q1 25Q4 24Q3 24Q2 24Q1 24Q2 23Q1 23Q4 22Q3 22% of revenueYoY
Licensing Fee [Member]––$10.36K$17.31K$14.94K$16.94K$16.06K$21.56K$20.03K$23.87K$18.63K$21.11K––
Equipment [Member]––$52.53K$19.81K$7.40K$18.80K$10.11K$1.51K$5.10K$6.40K$4.75K$4.10K––
Other [Member]––$7.71K$3.89K$4.84K$288$668$100$807$290$275$110––
Device Sales [Member]––––$0$0$0$55.50K$9.60K–$0$520.00K––
Royalty Fee [Member]––––––––––$14.78K–––

By region

RevenueQ2 26Q1 26Q2 25Q1 25Q4 24Q3 24Q2 24Q1 24Q2 23Q1 23Q4 22Q3 22% of revenueYoY
United States$12.16K$14.95K$11.11K$20.44K$17.95K$20.66K$21.69K$23.17K$25.33K$30.56K$23.68K$25.32K100.0%+9.4%
China––$59.48K$20.57K––$5.15K$55.50K$10.21K–$14.75K$520.00K––
International Sales [Member]–––––$15.37K$5.15K$55.50K$10.21K–––––
International [Member]––$59.48K$20.57K––––––––––

From the segment and revenue-disaggregation notes of Nexalin Technology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.